Kings Point Capital Management’s Trinity Biotech TRIB Stock Holding History

Kings Point Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,749	Closed	-$103K	–	340
2015 Q4	$103K	Hold	1,749	–	–	0.03%	152
2015 Q3	$100K	Hold	1,749	–	–	0.03%	172
2015 Q2	$158K	Hold	1,749	–	–	0.04%	139
2015 Q1	$168K	Hold	1,749	–	–	0.04%	134
2014 Q4	$153K	Sell	1,749 -10,638	-86%	-$917K	0.04%	129
2014 Q3	$1.13M	Buy	12,387 +3,898	+46%	+$422K	0.34%	55
2014 Q2	$978K	Sell	8,489 -8,514	-50%	-$1.01M	0.29%	55
2014 Q1	$2.06M	Buy	17,003 +4,635	+37%	+$608K	0.67%	46
2013 Q4	$1.55M	Buy	12,368 +4,613	+59%	+$554K	0.54%	48
2013 Q3	$844K	Buy	7,755 +6,155	+385%	+$600K	0.32%	59
2013 Q2	$135K	Buy	+1,600	New	+$133K	0.05%	115

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Kings Point Capital Management's TRIB Position: Q1 2016 in Review

Kings Point Capital Management sold out of Trinity Biotech (TRIB) in Q1 2016, closing a stake of 1,749 shares — an estimated $103K sold.

Kings Point Capital Management first reported a position in TRIB in Q2 2013 and held it in 11 quarters. The position peaked at $2.06M in Q1 2014. 79 funds tracked by Wall St. Rank hold TRIB as of Q1 2016.

Kings Point Capital Management reported no remaining Trinity Biotech position as of Q1 2016 after selling out during the quarter.
Kings Point Capital Management sold 1,749 Trinity Biotech shares in Q1 2016, an estimated $103K.
Kings Point Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 11 quarters.
Kings Point Capital Management's Trinity Biotech position peaked at $2.06M in Q1 2014.
79 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2016.

Based on Kings Point Capital Management's 13F filing for Q1 2016, filed 12 May 2016.